Enteric fever and its impact on returning travellers

International Health

Volumn 7, Issue 3, 2015, Pages 163-168

  Dave, Jayshree ^a   Sefton, Armine ^b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antibiotic resistance; Enteric fever; Travellers; Vaccine

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DRINKING WATER; GATIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; TRIMETHOPRIM; TYPHOID VACCINE; ANTIINFECTIVE AGENT; TYPHOID PARATYPHOID VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL TRANSMISSION; BONE MARROW TOXICITY; CLINICAL FEATURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMPORIATRICS; ENDEMIC DISEASE; ENVIRONMENTAL SANITATION; HEALTH PROMOTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SALMONELLA ENTERICA SEROVAR PARATYPHI A; SALMONELLA ENTERICA SEROVAR PARATYPHI B; SALMONELLA ENTERICA SEROVAR PARATYPHI C; SALMONELLA ENTERICA SEROVAR TYPHI; SINGLE DRUG DOSE; SOUTH ASIA; SYSTEMATIC REVIEW (TOPIC); TRAVEL; TREATMENT DURATION; TYPHOID FEVER; UNSPECIFIED SIDE EFFECT; WATER CONTAMINATION; DRUG RESISTANCE; MICROBIOLOGY; PARATYPHOID FEVER;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFTRIAXONE; DRUG RESISTANCE; HUMANS; PARATYPHOID FEVER; SALMONELLA PARATYPHI A; SALMONELLA PARATYPHI B; SALMONELLA PARATYPHI C; SALMONELLA TYPHI; TRAVEL; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

EID: 84930066101     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1093/inthealth/ihv018     Document Type: Article

References (59)

1. Papagrigorakis MJ, Yapijakis C, Synodinos PN, Baziotopoulou-Valavani E. DNA examination of ancient dental pulp incriminates typhoid fever as a probable cause of the Plague of Athens. Int J Infect Dis 2006;10:206-14.
2. Shapiroa B, Rambauta A, Gilbert N. No proof that typhoid caused the Plague of Athens (a reply to Papagrigorakis et al.) Int J Infect Dis 2006;10:334-5.
3. World Tourism Organization. UNWTO tourism highlights: 2014 edition. http://mkt.unwto.org/publication/unwto-tourism-highlights-2014-edition [accessed 5 September 2014].
4. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. Clin Infect Dis 2010;50:241-6.
5. Buckle GC, Fischer Walker CL, Black RE. Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2012;2:010401.
6. Tourdjman M, Le Hello S, Gossner C et al. Unusual increase in reported cases of Paratyphoid A fever among travellers returning from Cambodia, January to September 2013. Euro Surveill 2013;18:1-5.
7. Arndt MB, Mosites EM, Tian M et al. Estimating the burden of paratyphoid A in Asia and Africa. PLoS Negl Trop Dis 2014;8:e2925.
8. Ochiai RL, Acosta CJ, Danovaro-Holliday MC et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ 2008;86:260-8.
9. Wain J, Hendriksen RS, Mikoleit ML et al. Typhoid fever. Lancet. 2014;pii:S0140-6736(13)62708-7.
10. Parry CM, Hien TT, Dougan G et al. Typhoid fever. N Engl J Med 2002;347:1770-82.
11. Gordon MA. Invasive nontyphoidal Salmonella disease: epidemiology, pathogenesis and diagnosis. Curr Opin Infect Dis 2011;24:484-9.
12. Waddington CS, Darton TC, Jones C. Outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis 2014;58:1230-40.
13. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
14. Maskey AP, Day JN, Phung PQ et al. Salmonella enterica Typhi and Paratyphi A cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006;42:1247-53.
15. Leder K, Torresi J, Brownstein JS et al. Travel-associated illness trends and clusters, 2000-2010. Emerg Infect Dis 2013;19:1049-57.
16. Health Protection Agency Migrant Health: Infectious diseases in non-UK born populations in England, Wales and Northern Ireland. An update to the baseline report - 2011. London: Health Protection Agency Centre for Infections; 2011. http://www.sepho.org.uk/viewResource.aspx?id=14340 [accessed 20 January 2015].
17. Greenaway CA, Schofield S, Henteleff A et al. Statement on international travellers and typhoid by the Committee to Advise on Tropical Medicine and Travel (CATMAT). Can Commun Dis Rep 2014;40:60-70.
18. Steffen R, Behrens RH, Hill DR et al. Vaccine-preventable travel health risks: what is the evidence-what are the gaps? J Travel Med 2015;22:1-12.
19. Public Health England. http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1206575041900 [accessed 20 February 2015].
20. Patel TA, Armstrong M, Morris-Jones SD et al. Imported enteric fever:case series from the hospital for tropical diseases, London, United Kingdom. Am J Trop Med Hyg 2010;82:1121-6.
21. Dave J, Millar M, Maxeiner H et al. East London experience with enteric fever 2007-2012. PLos One 2015;10:e0120926.
22. Comeau JL, Tran TH, Moore DL et al. Salmonella enterica serotype Typhi infections in a Canadian pediatric hospital: a retrospective case series. CMAJ Open 2013;1:E56-61.
23. Barrett FC, Dahl Knudsen J, Johansen IS. Cases of typhoid fever in Copenhagen region: a retrospective study of presentation and relapse. BMC Res Notes 2013;6:315.
24. Gunaratnam P, Tobin S, Seale H, McAnulty JM. Infectious diseases in returned travellers, NSW, 2010-2011. NSW Public Health Bulletin 2014;24:171-5.
25. National Travel Health Network and Centre (NaTHNaC). Health professionals. Health information sheets. https://www.nathnac.org/pro/factsheets/typhoid.htm [accessed 20 February 2015].
26. Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 2005;5:623-8.
27. Whitaker JA, Franco-Paredes C, del Rio C, Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009;16:46-52.
28. Wilder-Smith A, Khairullah NS, Song JH et al. Travel health knowledge, attitudes and practices among Australasian travelers. J Travel Med 2004;11:9-15.
29. Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines:a metaanalysis of studies on efficacy and toxicity. BMJ 1998;316:110-6.
30. Public Health England. Typhoid: the green book, chapter 33. https://www.gov.uk/government/publications/typhoid-the-green-book-chapter-33 [accessed 14 July 2014].
31. Waddington C, Darton T, Pollard A. The challenge of enteric fever. J Infect 2014;68(Supp 1):S38-50.
32. Anwar E, Goldberg E, Fraser A et al. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2014;1:CD001261.
33. Medicines and Healthcare products Regulatory Agency (MHRA). Press release: Typhoid vaccine batches recalled by manufacturer Sanofi. http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON192154 [accessed 4 November 2014].
34. National Travel Health Network and Centre (NaTHNaC). Supply of typhoid and hepatitis A/typhoid (combined) vaccines-update. https://www.nathnac.org/pro/clinical_updates/vacc_supply_011012.htm [accessed 4 November 2014].
35. Lin FY, Ho VA, Khiem HB et al. The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001;344:1263-9.
36. Stuart BM, Pullen RL. Typhoid: clinical analysis of 360 cases. Arch Intern Med 1946;78:629-61.
37. Van den Bergh ETAM, Gasem MH, Keuter M, Dolmans MV. Outcome in three groups of patients with typhoid fever in Indonesia between 1948 and 1990. Trop Med Int Health 1999;4:211-5.
38. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005;366:749-62.
39. Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J Med Microbiol 1996;44:317-9.
40. Bethell DB, Day NP, Dung NM et al. Pharmacokinetics of oral and intravenous ofloxacin in multi-drug-resistant typhoid fever. Antimicrob Agents Chemother 1996;40:2167-72.
41. Hassing RJ, Goessens WH, Mevius DJ et al. Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. Eur J Clin Microbiol Infect Dis 2013;32:1295-301.
42. Hume S, Schulz T, Vinton P et al. Increasing rates and clinical consequences of nalidixic acid-resistant isolates causing enteric fever in returned travellers: an 18-year experience. Eur J Clin Microbiol Infect Dis 2009;28:963-70.
43. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. http://www.eucast.org [accessed 4 November 2014].
44. BSAC. BSACMethods for Antimicrobial Susceptibility Testing. BSAC. http://bsac.org.uk/wp-content/uploads/2012/02/Version-12-Apr-2013_final.pdf [accessed 4 November 2014].
45. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
46. Effa EE, Lassi ZS, Critchley JA et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2011;10:CD004530.
47. Effa E, Bukirwa H. Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2008;4:1-36.
48. Dolecek C, Tran TP, Nguyen NR et al. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid and paratyphoid fever in children and adults in Vietnam. PLoS One 2008;3:e2188.
49. Arjyal A, Basnyat B, Koirala S et al. Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. Lancet Infect Dis 2011;11:445-54.
50. Rai S, Jain S, Prasad KN et al. Rationale of azithromycin prescribing practices for enteric fever in India. Indian J Med Microbiol 2012;30:30-3.
51. Hassing RJ, Goessens WH, van Pelt W et al. Salmonella subtypes with increased MICs for azithromycin in travelers returned to The Netherlands. Emerg Infect Dis 2014;20:705-8.
52. Bhutta ZA, Khan IA, Shadmani M. Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. Antimicrob Agents Chemother 2000;44:450-2.
53. Islam A, Butler T, Kabir I, Alam NH. Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial. Antimicrob Agents Chemother 1993;37:1572-5.
54. Tatli MM, Aktas G, Kosecik M, Yilmaz A. Treatment of typhoid fever in children with a flexible-duration of ceftriaxone, compared with 14-day treatment with chloramphenicol. Int J Antimicrob Agents 2003;21:350-3.
55. Karki S, Shakya P, Cheng AC et al. Trends of etiology and drug resistance in enteric fever in the last two decades in Nepal: a systematic review and meta-analysis. Clin Infect Dis 2013;57:167-76.
56. Bhattacharya SS, Das U, Choudhury BK. Occurrence & antibiogram of Salmonella Typhi & S. Paratyphi A isolated from Rourkela, Orissa. Indian J Med Res 2011;133:431-3.
57. Gokul BN, Menezes GA, Harish BN. ACC-1 β-Lactamase-producing Salmonella enterica Serovar Typhi, India. Emerg Infect Dis 2010;16:1170-1.
58. Khanam F, Sheikh A, Sayeed MA et al. Evaluation of a typhoid/paratyphoid diagnostic assay (TPTest) detecting anti-Salmonella IgA in secretions of peripheral blood lymphocytes in patients in Dhaka, Bangladesh. PLoS Negl Trop Dis 2013;7:e2316.
59. WHO. Background document: The diagnosis, treatment and prevention of typhoid fever. Geneva: World Health Organization; 2003.